Common Genetic Variants in Prostate Cancer Risk Prediction—Results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3)

Background: One of the goals of personalized medicine is to generate individual risk profiles that could identify individuals in the population that exhibit high risk. The discovery of more than two-dozen independent single-nucleotide polymorphism markers in prostate cancer has raised the possibility for such risk stratification. In this study, we evaluated the discriminative and predictive ability for prostate cancer risk models incorporating 25 common prostate cancer genetic markers, family history of prostate cancer, and age. Methods: We fit a series of risk models and estimated their performance in 7,509 prostate cancer cases and 7,652 controls within the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). We also calculated absolute risks based on SEER incidence data. Results: The best risk model (C-statistic = 0.642) included individual genetic markers and family history of prostate cancer. We observed a decreasing trend in discriminative ability with advancing age (P = 0.009), with highest accuracy in men younger than 60 years (C-statistic = 0.679). The absolute ten-year risk for 50-year-old men with a family history ranged from 1.6% (10th percentile of genetic risk) to 6.7% (90th percentile of genetic risk). For men without family history, the risk ranged from 0.8% (10th percentile) to 3.4% (90th percentile). Conclusions: Our results indicate that incorporating genetic information and family history in prostate cancer risk models can be particularly useful for identifying younger men that might benefit from prostate-specific antigen screening. Impact: Although adding genetic risk markers improves model performance, the clinical utility of these genetic risk models is limited. Cancer Epidemiol Biomarkers Prev; 21(3); 437–44. ©2012 AACR.

[1]  Fredrik Wiklund,et al.  Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer , 2011, The Prostate.

[2]  M. Pepe,et al.  Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. , 2004, American journal of epidemiology.

[3]  O. Bratt What should a urologist know about hereditary predisposition to prostate cancer? , 2007, BJU international.

[4]  Ali Amin Al Olama,et al.  Multiple newly identified loci associated with prostate cancer susceptibility , 2008, Nature Genetics.

[5]  Thomas J. Wang,et al.  Assessing the Role of Circulating, Genetic, and Imaging Biomarkers in Cardiovascular Risk Prediction , 2011, Circulation.

[6]  P. Visscher,et al.  The Genetic Interpretation of Area under the ROC Curve in Genomic Profiling , 2010, PLoS genetics.

[7]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.

[8]  M. Gail Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. , 2009, Journal of the National Cancer Institute.

[9]  R. Newson Confidence Intervals for Rank Statistics: Somers’ D and Extensions , 2006 .

[10]  James Waterman Glover United States Life Tables , 2013 .

[11]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[12]  W. Dupont Converting relative risks to absolute risks: a graphical approach. , 1986, Statistics in medicine.

[13]  R. Wilkins Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.

[14]  Peter Kraft,et al.  Characterizing Associations and SNP-Environment Interactions for GWAS-Identified Prostate Cancer Risk Markers—Results from BPC3 , 2011, PloS one.

[15]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[16]  Roderick J. A. Little,et al.  Single Imputation Methods , 2014, Statistical Analysis with Missing Data, Third Edition.

[17]  F. Eugene Yates,et al.  The national center for health statistics , 1973, Annals of Biomedical Engineering.

[18]  Carmen Rodriguez,et al.  The American Cancer Society Cancer Prevention Study II Nutrition Cohort , 2002, Cancer.

[19]  D. English,et al.  Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and Risk of Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[20]  M. Stampfer,et al.  Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. , 2002, Journal of the National Cancer Institute.

[21]  M. Kattan,et al.  The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. , 2008, European urology.

[22]  E. Rimm,et al.  Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[23]  A. Vickers,et al.  Estimating the benefits of PSA screening , 2022 .

[24]  Sally R. Hinchliffe,et al.  Combining 33 genetic variants with prostate‐specific antigen for prediction of prostate cancer: Longitudinal study , 2012, International journal of cancer.

[25]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[26]  Martin Eklund,et al.  Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. , 2011, European urology.

[27]  A. Gylfason,et al.  Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels , 2010, Science Translational Medicine.

[28]  J. Gohagan,et al.  Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. , 2000, Controlled clinical trials.

[29]  J. Martin,et al.  National Vital Statistics Reports , 2002 .

[30]  M. Stampfer,et al.  Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. , 2002, Journal of the National Cancer Institute.

[31]  Andrew J Vickers,et al.  Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Easton,et al.  Polygenic susceptibility to prostate and breast cancer: implications for personalised screening , 2011, British Journal of Cancer.

[33]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[34]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[35]  Mitchell H Gail,et al.  Personalized estimates of breast cancer risk in clinical practice and public health , 2011, Statistics in medicine.

[36]  N E Day,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.

[37]  D. Altshuler,et al.  The multiethnic cohort study: exploring genes, lifestyle and cancer risk , 2004, Nature Reviews Cancer.